Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. The company is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Mr. Zackary Irani est le Chief Executive Officer de Biomerica Inc, il a rejoint l'entreprise depuis 1994.
Quelle est la performance du prix de l'action BMRA ?
Le prix actuel de BMRA est de $2, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Biomerica Inc ?
Biomerica Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Biomerica Inc ?
La capitalisation boursière actuelle de Biomerica Inc est de $6.0M
Est-ce que Biomerica Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Biomerica Inc, y compris 3 achat fort, 3 achat, 1 maintien, 0 vente et 3 vente forte